ALKS 29

DB05723ExperimentalSmall molecule

ALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.

Primary indication
Investigated for use/treatment in addictions and alcohol dependence.Curator reviewed
Code names
ALKS 29

What you can answer from here — as of April 02, 2025

1+ReferenceStructured and connected to the statements they support
Sign in

Which companies are running trials of ALKS 29, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In